teva pharmaceutical industries stock: Complete Guide

Teva Pharmaceutical Industries (TEVA) stock

This article explains teva pharmaceutical industries stock for investors and beginners. It covers what teva pharmaceutical industries stock is, where it trades, how to find market data, the company's business drivers and risks, recent measurable indicators and notable dates, and practical trading considerations including how to monitor price, volume and corporate disclosures. Readers will learn where to check live quotes and filings and how to use reliable sources like the company investor relations pages and major market data providers. For trading access and custody options, consider checking Bitget for available equity services and Bitget Wallet for secure asset custody and record‑keeping.

As of 2026-01-27, according to Yahoo Finance and the company investor relations site, teva pharmaceutical industries stock trades as an ADR in U.S. markets and remains a heavily followed security by analysts and institutional holders.

Company overview

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company primarily known for its generics business and a portfolio of specialty branded medicines. The firm operates across multiple areas including central nervous system (CNS) therapies, respiratory medicines, oncology collaborations, biosimilars, active pharmaceutical ingredient (API) manufacturing, and contract manufacturing services.

Teva was founded in the mid‑20th century and is headquartered in Israel. Its product mix historically included large generics franchises alongside specialty drugs — notable legacy products and contributions include multiple formulations in neurology and respiratory care. The company maintains R&D programs, in‑licensing arrangements, and partnerships to support its specialty and biosimilar pipelines.

The company's global footprint spans multiple regions with manufacturing sites, R&D centers and commercial operations in the Americas, Europe, Asia and Israel. These geographic operations create exposure to foreign exchange, regional regulatory regimes, and cross‑border supply chain considerations that influence teva pharmaceutical industries stock performance.

Stock listings and identifiers

• Primary U.S. listing: teva pharmaceutical industries stock is commonly quoted as TEVA (ADR) on U.S. exchanges. U.S. investors typically trade the American Depositary Receipts (ADRs) representing ordinary shares held in custody abroad.
• Home market listing: Teva also maintains listings in Israel and may have local tickers for its ordinary shares on the Tel Aviv exchange; consult the company investor relations for exact local ticker and share class mechanics.
• Identifiers: institutional investors use standard identifiers such as ISIN and SEDOL to identify securities across systems. The ADR structure means each ADR represents a specified number of underlying ordinary shares (ADR mechanics, ratio and fees are published by the depositary bank and in Teva’s investor materials).

For precise ticker, ADR ratio, ISIN and depositary details, see the company investor relations disclosures and official exchange listing pages. These pages also explain dividend conversion, currency settlement, and ADR surrender mechanics for investors wishing to convert ADRs back to ordinary shares.

Market data and key trading information

Investors reference a set of standard market metrics when evaluating teva pharmaceutical industries stock. Typical live data elements include:

• Last trade price and quoted currency (U.S. dollar for ADRs).
• Market capitalization — aggregate equity value based on price and shares outstanding.
• Shares outstanding and public float — number of issued shares and portion available for trading.
• Average daily trading volume — a liquidity indicator (shares traded per day).
• 52‑week high and low — the price range over the prior year.
• Beta — a statistical measure of historical volatility relative to a market benchmark.
• Bid/ask spreads and intraday liquidity characteristics.

As of 2026-01-27, according to published snapshots on Yahoo Finance and Morningstar, teva pharmaceutical industries stock shows measurable liquidity with multi‑million share daily volume and a market capitalization reported on public data platforms. For live, timestamped market data (price, market cap, volume, 52‑week range), use major market data providers such as Yahoo Finance, Morningstar, CNBC or the company IR quote pages. These sources update continuously; cite them for exact numbers at the time you trade.

Historical price performance

Teva’s share price has experienced multi‑year volatility driven by generics pricing pressures, litigation outcomes, portfolio restructuring, and business cycle events in branded medicines. Over 1‑, 5‑ and 10‑year horizons, teva pharmaceutical industries stock has had periods of recovery and decline corresponding to corporate announcements, patent expirations, and sector‑wide generics market dynamics.

Important historical events that shaped price performance include large acquisitions or divestitures, major litigation settlements, and key product lifecycle milestones. Investors often compare teva pharmaceutical industries stock returns to broad indices such as the S&P 500 and to peers in the generics and specialty pharmaceutical sectors to gauge relative performance.

Financial metrics and recent results

Key financial metrics used to analyze teva pharmaceutical industries stock include:

• Revenue and revenue growth (quarterly and yearly).
• Net income or loss and adjusted earnings measures (adjusted EPS).
• EBITDA and adjusted EBITDA (operating profitability metric).
• Trailing and forward P/E ratios where applicable (earnings may be negative in some periods).
• Price/sales and enterprise value/EBITDA multiples for valuation comparisons.
• Leverage ratios including net debt/EBITDA and interest coverage, important for a company with sizeable debt.

As of the most recent quarterly filings, the company’s reported revenue, adjusted EBITDA and guidance (if provided) are published in its earnings release and accompanying investor presentation. For example, the company’s latest quarterly report and presentation (see investor relations) include detailed line‑by‑line reconciliations for adjusted measures and management commentary on drivers such as generics pricing, specialty product performance and cost controls.

Earnings releases and guidance

Quarterly earnings releases are primary sources for updated financial performance and management outlook. These releases typically provide:

• Revenue and EPS versus analyst consensus.
• Management commentary on drivers and headwinds.
• Updated guidance ranges for upcoming quarters or full year when provided.

As of the latest earnings date, and according to Teva’s investor relations release published on the company site, management presented quarterly results and issued commentary on operational progress. For precise dates and figures, consult the company’s earnings press release and the filings repository for official audited numbers.

Dividends and corporate actions

Teva’s dividend history, share buyback activity and other capital allocation decisions can materially affect the yield and total shareholder returns. Historically, the company has adjusted dividends in response to cash generation and leverage priorities.

Investors should monitor:

• Dividend declarations, ex‑dividend dates, record dates, and payable dates.
• Dividend yield (annualized dividend divided by share price at a point in time).
• Share repurchase programs and authorization sizes.
• Stock splits or ADR ratio changes (rare for Teva in recent years).

Dividend payments on ADRs may be subject to conversion fees and withholding taxes depending on jurisdiction; check the depositary bank details and company dividend policy published in investor materials.

Major shareholders and insider holdings

Institutional ownership commonly represents a significant portion of teva pharmaceutical industries stock, with large mutual funds, pension funds and global asset managers often reported as top holders. Insider ownership (executive officers, board members) and recent insider transactions are disclosed in regulatory filings and can be reviewed for potential signalling of management confidence.

Activist positions or large institutional stakes, when announced, can influence corporate strategy and investor expectations. For the latest institutional ownership percentages and top holders, consult regulatory filings and data aggregators such as Morningstar and company disclosure pages.

Analyst coverage and price targets

Sell‑side analysts and independent research outlets cover teva pharmaceutical industries stock with ratings and price targets that reflect expectations for earnings, growth and risk. Coverage typically includes:

• Buy / Hold / Sell recommendations and consensus ratings.
• Median and range of analyst price targets.
• Earnings estimates and revisions that drive implied forward multiples.

Major financial news platforms and brokerage summaries aggregate analyst actions and publish updated target ranges. For example, investor platforms often display the consensus distribution alongside recent revisions; track these changes around earnings, product news, or material legal developments.

Key business and regulatory drivers affecting the stock

The following drivers commonly move teva pharmaceutical industries stock:

• Generics pricing environment: margin pressure or recovery in generic drug pricing affects revenue and gross margins.
• Specialty branded product performance: launches, uptake, and lifecycle events for specialty drugs such as neurology or other therapeutic area products.
• Patent expirations and successful defenses: patent expiries allow generic entrants that can reduce revenue for branded products.
• Biosimilars and pipeline progress: approvals and commercial launches in biosimilars and specialty pipelines create new revenue streams and strategic optionality.
• R&D outcomes: clinical trial results, regulatory approvals or denials materially change forward revenue expectations.
• Partnerships, licensing deals and divestitures: M&A activity or licensing can reshape the portfolio and balance sheet dynamics.
• Regulatory and legal developments: settlements, fines, or adjudications related to litigation and compliance issues.

Each item above is monitored by investors because they directly affect revenue trajectories, margin profiles and the company’s leverage recovery path — all core elements that determine the valuation of teva pharmaceutical industries stock.

Risks and controversies

Investors should be aware of principal risks that can affect teva pharmaceutical industries stock valuation:

• Litigation and regulatory risk: large legal settlements or ongoing mass torts can produce uncertain liabilities.
• Patent cliffs and competitive generic entry: loss of exclusivity on key products can dramatically reduce revenue.
• High leverage: elevated net debt magnifies financial risk and constrains flexibility for investment or dividends.
• Generics pricing pressure: pricing competition and tender dynamics can compress margins in the generics segment.
• Operational and supply chain risks: manufacturing quality issues or disruptions can affect product availability and reputation.
• Currency and geopolitical exposure: operating across multiple jurisdictions exposes the company to FX swings and geopolitical regulatory risks.

Reported legal matters and settlement values are detailed in company filings and major financial news sources. As of recent reporting windows, Teva disclosed material legal reserves and settlement arrangements; see the company’s annual report and SEC/Israeli filings for specifics and dates.

Corporate governance and investor relations

Teva’s board structure, executive leadership and governance policies are disclosed in proxy statements and annual reports. Investors can review:

• Board composition and committee responsibilities.
• Executive compensation and incentive structures.
• Corporate governance practices and shareholder rights.
• Investor relations contacts, presentation decks and conference call transcripts.

The investor relations page on the company website provides access to filings, press releases, earnings materials and webcast replays for quarterly calls. These official resources are primary sources for validated company disclosures.

Recent news and market reactions

As of 2026-01-27, several news items have influenced investor sentiment in the pharmaceutical sector and in teva pharmaceutical industries stock specifically. For example:

• As of 2026-01-20, according to a market summary on Yahoo Finance, several analyst notes discussed updated revenue outlooks for generics companies after recent pricing changes in key markets.
• As of 2026-01-15, Morningstar and other platforms published sector commentary noting how biosimilar approvals could alter specialty revenue prospects across multiple firms.

When material company news (earnings beats/misses, legal settlements, regulatory approvals) is reported, teva pharmaceutical industries stock often shows intraday volatility as markets price the new information. Use reputable financial news sources and the company’s IR releases for timestamped reporting and to verify the facts behind price moves.

Trading, investment considerations and strategies

Practical matters for traders and investors considering teva pharmaceutical industries stock:

• Liquidity & volatility: TEVA ADRs typically have substantial average daily volume — check recent averages on market data platforms to assess execution risk.
• Derivatives availability: Options markets may exist on TEVA; verify option chain liquidity before using options‑based strategies.
• Tax and ADR considerations: ADR dividends, withholding and tax treatments differ by investor residence — consult tax advisors and depositary documentation.
• Fundamental vs event‑driven investing: long‑term investors often focus on balance sheet repair, cash flow and pipeline progress; event‑driven traders monitor legal decisions, approvals and quarterly beats/misses for short‑term moves.

For trading access and custody, consider Bitget’s trading services and Bitget Wallet for record‑keeping and security. Verify available instruments and jurisdictional availability on Bitget before placing orders.

Historical and regulatory events (selected)

Selected events that materially affected teva pharmaceutical industries stock include large settlements, major acquisitions, and regulatory rulings. Examples (dates and sources should be checked against official filings):

• Large litigation settlements announced and resolved in prior years — detailed in annual reports and regulatory filings.
• Significant portfolio transactions (acquisitions or divestitures) announced with financial terms and strategic rationale disclosed in press releases.
• Patent litigation outcomes and regulatory approvals/denials for key products that reshaped expected revenue over multi‑year windows.

Whenever assessing the impact of historical events, reference the company’s filings and reputable financial news archives for source documents and press dates.

See also

• Teva Pharmaceutical Industries — company overview and public filings.
• Generics pharmaceuticals sector — market dynamics and pricing trends.
• American Depositary Receipts (ADRs) — mechanics and investor considerations.
• Competitors in generics and specialty pharma — for relative valuation and peer benchmarking.

References

The following public data providers and company resources are primary sources for teva pharmaceutical industries stock data and disclosures: company investor relations and filings, Yahoo Finance (live quotes), Morningstar (fundamental data), CNBC market pages (news & quotes), Robinhood and other brokerage summaries, The Motley Fool commentary, and company press releases and regulatory filings (SEC / Israeli filings). For the most up‑to‑date numeric values (market cap, volume, EPS), consult these sources on the date and time of your decision.

• As of 2026-01-27, live market snapshots and consolidated data were referenced from Yahoo Finance and Morningstar.
• As of 2026-01-20, sector commentary and analyst note summaries were available on CNBC and Morningstar.

External links

• Teva investor relations (official company site) — for filings, investor presentations, and earnings materials.
• Major market data platforms (Yahoo Finance, Morningstar, CNBC) — for live price and historical charts.

Further exploration: monitor teva pharmaceutical industries stock on your preferred market data platform and review the company’s latest quarterly report and investor presentation before making any trading decisions. To trade or custody equities, check Bitget for available instruments and Bitget Wallet for secure record‑keeping.

Important notes: This article is educational and neutral in tone. It summarizes publicly available information about teva pharmaceutical industries stock and points readers to primary sources. It is not investment advice. For live numbers and filings, always consult the company investor relations pages and real‑time market data providers. Reporting dates above indicate when referenced public commentary or snapshots were available.